Cytune Pharma

Institut National De La Sante Et De La Recherche Medicale

Institut Pasteur De Lille

Assistance Publique-Hopitaux De Paris

Institut Gustave Roussy

Université De Paris

Université Paris Descartes

Universite Paris Cité

Inserm

David Bechard

Sebastien Daniel Morisseau

Yannick Laurent Joseph Jacques

Bruno Gilbert Marc Robert

Guy Luc Michel De Martynoff

Geraldine Teppaz

Guy De Martynoff

André-Bernard Tonnel

Eric Tartour

Philippe Lassalle

Géraldine Teppaz

Alain Gey

Melanie Desbois

Nathalie Chaput

Philipp Lassalle

Guy Luc De Martynoff

Bruno Gilbert Robert

Sébastien Daniel Morisseau

Mélanie Desbois

Yannick Laurent Jacques

The present invention relates to a method for preparing a composition comprising monomeric conjugates from a sample, said conjugate comprising (a) a polypeptide comprising the amino acid sequence of interleukin 15 or derivatives thereof, and (b) a polypeptide comprising the amino acid sequence of the sushi domain of IL-15Rα or derivatives thereof; wherein said method comprises the use of anion-exchange chromatography followed by a hydrophobic interaction chromatography; and to a pharmaceutical composition which can be obtained by such a method.

IL-15/IL-15Ralpha based conjugates purification method

The present invention relates to an immunocytokine comprising (a) a conjugate, and (b) an antibody or a fragment thereof directly or indirectly linked by covalence to said conjugate, wherein said conjugate comprises (i) a polypeptide comprising the amino acid sequence of the interleukin 15 or derivatives thereof, and (ii) a polypeptide comprising the amino acid sequence of the sushi domain of the interleukin 15R alpha (IL-15R&#x3b1;) or derivatives thereof; and uses thereof.

IL-15 and IL-15R\alpha sushi domain based immunocytokines

The present invention relates to a pharmaceutical composition for treating a cancer or an infection in a subject by administrating an amount of an interleukin 15 (IL-15) derivative conjugate so as to induce a proliferation of natural killer cells (NK cells) which is the same or higher than the one obtained with high dose of interleukin-2 (HDIL-2); eventually associated with a pharmaceutically acceptable carrier.

Cytokine derived treatment with reduced vascular leak syndrome

The present invention relates to an immunocytokine comprising (a) a conjugate, and (b) an immunomodulatory antibody or a fragment thereof directly or indirectly linked by covalence to said conjugate, wherein said conjugate comprises (i) a polypeptide comprising the amino acid sequence of the interleukin 15 or derivatives thereof, and a polypeptide comprising the amino acid sequence of the sushi domain of the IL-15R&#x3b1; or derivatives thereof; and uses thereof.

IL-15 and IL-15RAPLHA sushi domain based immunocytokines

IL-15 and IL-15R&#x3b1; sushi domain based immunocytokines

The present invention relates to a method for preparing a composition comprising monomeric conjugates from a sample, said conjugate comprising (a) a polypeptide comprising the amino acid sequence of interleukin 15 or derivatives thereof, and (b) a polypeptide comprising the amino acid sequence of the sushi domain of IL-15R&#x3b1; or derivatives thereof; wherein said method comprises the use of anion-exchange chromatography followed by a hydrophobic interaction chromatography; and to a pharmaceutical composition which can be obtained by such a method.

The invention concerns a kit for the detection of protein ESM-1 in a sample, comprising:

Kit and method for detecting the ESM-1 protein

Use of an antagonist compound of protein ESM-1 for the production of a drug for the treatment of a cancer.

Use of a compound antagonist of ESM-1 protein for producing a medicine for treating cancer

Growing community of inventors

Saint-Etienne de Montluc, France

David Bechard